Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
1.230
-0.070 (-5.38%)
At close: Oct 9, 2025, 4:00 PM EDT
1.230
0.00 (0.00%)
After-hours: Oct 9, 2025, 4:00 PM EDT

Company Description

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.

Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Estrella Immunopharma, Inc.
Estrella Immunopharma logo
CountryUnited States
Founded2021
IndustryBiotechnology
SectorHealthcare
CEOCheng Liu

Contact Details

Address:
5858 Horton Street, Suite 370
EmeryVille, California 94608
United States
Phone510 318 9098
Websiteestrellabio.com

Stock Details

Ticker SymbolESLA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001844417
CUSIP Number297584104
ISIN NumberUS2975841048
Employer ID86-1314502
SIC Code2836

Key Executives

NamePosition
Dr. Cheng Liu Ph.D.Chief Executive Officer, President and Director
Jiandong XuChief Financial Officer

Latest SEC Filings

DateTypeTitle
Sep 29, 20258-KCurrent Report
Sep 26, 20258-KCurrent Report
Aug 12, 202510-QQuarterly Report
Aug 7, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report
Jun 3, 20258-KCurrent Report
May 29, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
May 2, 20258-KCurrent Report
Mar 25, 202510-KTFiling